Furthermore, EpoL—a rhEPO variant with low glycosylation and deprived of hematopoietic effect—displays a more powerful neuroprotective profile against oxidative stress with respect to the canonical EPO isoforms in an in vitro model of PD using PC12 cells [41]. Here, EPO is linked to Parkinson disease.